StageZero Life Sciences (OTCMKTS:GNWSD) and IDEXX Laboratories (NASDAQ:IDXX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.
Valuation & Earnings
This table compares StageZero Life Sciences and IDEXX Laboratories’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|StageZero Life Sciences||$140,000.00||255.12||-$3.48 million||N/A||N/A|
|IDEXX Laboratories||$2.41 billion||17.63||$427.72 million||$4.89||101.75|
This table compares StageZero Life Sciences and IDEXX Laboratories’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|StageZero Life Sciences||217.39%||N/A||-61.21%|
This is a summary of recent ratings for StageZero Life Sciences and IDEXX Laboratories, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|StageZero Life Sciences||0||0||0||0||N/A|
IDEXX Laboratories has a consensus target price of $395.67, suggesting a potential downside of 20.48%. Given IDEXX Laboratories’ higher probable upside, analysts plainly believe IDEXX Laboratories is more favorable than StageZero Life Sciences.
Insider & Institutional Ownership
82.6% of IDEXX Laboratories shares are held by institutional investors. 2.5% of IDEXX Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Risk & Volatility
StageZero Life Sciences has a beta of 2.97, meaning that its share price is 197% more volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.
IDEXX Laboratories beats StageZero Life Sciences on 8 of the 11 factors compared between the two stocks.
StageZero Life Sciences Company Profile
StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. Its products includes Sentinel Principle, and ColonSentry. The company was founded by Choong-Chin Liew and K. Wayne Marshall in 1998 and is headquartered in Markham, Canada.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Receive News & Ratings for StageZero Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StageZero Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.